British pharmaceutical giant, AstraZeneca PLC (LON:AZN) today received approval from the European Commission for its Bydureon BCise ( a pre-filled pen device) which will enable patients with Type 2 Diabetes to medicate once a week.
Currently trading on a loss at 5,856.00 GBX −33.00 (0.56%) BST 08.37 as the UK Benchmark Index struggles to gain ground on the back of the strong GBP, this approval could have a major impact on Astrazeneca PLC’s profit margins.
An additional treatment option
A statement from the company read: “Today’s approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exercise.” as reported by Proactive Investors.
AstraZeneca PLC frozen dividends could be offset by 2019
AstraZeneca PLC reported sales growth of almost 40% in its second quarter reports for 2018, and with this latest approval being just one of many pending patents (including 2 innovative cancer treatments), the company looks set to increase its revenues in 2019 for the first time in 4 years. Chief Executive, Pascal Soriot stated in July’s half-year report: “AstraZeneca’s rich pipeline and sharp commercial focus make us confident that we have in place the right conditions for our return to growth this year.” as reported in Bio Space.
Astrazenca PLC slowly emerging from sustained period of decline
AstraZeneca PLC (LON:AZN) seems to be remerging from a long period of decline with the share price rising by almost 20% this year and analysts predicting a 15% rise in earnings in 2019